Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects.
about
Fermented milk for hypertensionInfluence of the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe scale of the evidence base on the health effects of conventional yogurt consumption: findings of a scoping reviewEffects of dairy on metabolic syndrome parameters: a review.Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects.IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomized controlled trial.Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials.Enhanced Lacto-Tri-Peptide Bio-Availability by Co-Ingestion of Macronutrients.Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trialsAntihypertensive Peptides from Milk ProteinsThe potential role of milk-derived peptides in cardiovascular disease.Review: Production and functionality of active peptides from milk.Possible role of milk-derived bioactive peptides in the treatment and prevention of metabolic syndrome.Inhibition of renin and the (pro)renin receptor system.Physiological properties of milk ingredients released by fermentation.Antihypertensive effects of bioactive tripeptides-a random effects meta-analysis.Antihypertensive peptides of animal origin: A review.Unraveling the mechanisms of action of lactoferrin-derived antihypertensive peptides: ACE inhibition and beyond.Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition?Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinicalScientific Opinion on the substantiation of health claims related to isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of normal blood pressure (ID 615, 661, 1831, 1832, 2891), and maintenance of the elastic propert...Scientific Opinion on the substantiation of a health claim related to isoleucyl‐prolyl‐proline (IPP) and valyl‐prolyl‐proline (VPP) and maintenance of normal blood pressure pursuant to Article 13(5) of Regulation (EC) No 1924/2006Scientific Opinion on the substantiation of health claims related to isoleucine‐proline‐proline (IPP) and valine‐proline‐proline (VPP) and maintenance of normal blood pressure (ID 661, 1831, 1832, 2891, further assessment) pursuant to Article 13(1...Effect of fermented milk product containing lactotripeptides and plant sterol esters on haemodynamics in subjects with the metabolic syndrome--a randomised, double-blind, placebo-controlled study.Predictors of the short-term effect of isoleucine-proline-proline/valine-proline-proline lactotripeptides from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high-normal blood pressure or first-degree hypeBlood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trialsEffects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects
P2860
Q24200294-4330E0AC-5F1F-407C-BD81-2A208C5B0DCEQ26780236-374BD272-4E7C-4F5F-81A6-633D6697C1D5Q26862491-2909E9CE-4632-4426-BE40-A8AB5B2D62AEQ33653074-930BE2CD-E84F-4436-8126-4B992C3C9E38Q33800305-54A1B021-A2D6-4A89-98B5-2E4752F54322Q34338348-8C020F4D-DB21-477F-B1DD-68B1CBC2B5B6Q35003895-AF6F662C-7FC3-479D-969C-1AC1090870E8Q35670341-47162CB4-3D47-420B-A84A-9FEB9571CC4CQ36590794-51774EBD-30F5-488E-A698-554F11A0CF75Q37709455-795CF1D6-3BE9-4F59-8091-20682D30F49EQ37903711-3D405F26-7233-48FF-8A65-E42F8C7D1F6CQ37932194-DADD7895-F009-4D48-9C21-13D518FA2DB7Q37998141-0EF64225-BC61-485A-A08A-24E6BAB2EF79Q38024862-EF4B9B68-DC0E-4B0F-9A52-5E6C1CDC4B6BQ38056616-C13F227A-C6BE-446C-A438-2B957B395E6CQ38072982-F3247C55-1C5D-43E8-97E6-7EB476E2F593Q38459630-24A301AA-9741-4AEB-80C1-820CF74201ACQ38541114-D05A5270-0AB1-443C-8212-815EE53F1B5FQ41883236-00F1BD0C-341C-43F0-9286-751446A59055Q46666157-BD27C9A6-E072-43CF-96CF-217501EB5186Q47147448-B0B1E61C-E6E7-420D-83F9-411261F1EFA6Q47150600-AA651301-8ED8-460C-916C-5E01156BDD20Q47151840-60C99C41-539D-4C9A-B554-48FD694DBB61Q53832680-C365EE8D-FE46-4A59-82FE-4AC2C7035FEDQ56983123-3438105E-FDB9-474D-A327-98E0A9FACDCBQ56985330-D796A6B0-B787-4D5B-9D0D-15253E5D6BA3Q57012126-248882C9-16A3-4238-9CE9-1BEC4FF72FBE
P2860
Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@ast
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@en
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@nl
type
label
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@ast
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@en
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@nl
prefLabel
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@ast
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@en
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@nl
P2093
P356
P1476
Enzymatically hydrolyzed lacto ...... mildly hypertensive subjects.
@en
P2093
Annette A A Bak
Kim van der Zander
Mettina M G Koning
Michiel L Bots
P304
P356
10.3945/AJCN.2008.26003
P407
P577
2008-12-01T00:00:00Z